Abstract:6080 Background: Seeking out a more effective and less-toxic regimen is necessary for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The aim of this study is to evaluate the efficacy and safety of neoadjuvant anti-programmed cell death-1 antibody tislelizumab combined with APF (albumin-bound paclitaxel, platinum and fluorouracil) followed by surgery or concurrent chemoradiotherapy. Methods: In this prospective, single-center, single-arm clinical study, previously untreated patients with locally advanced HNSCC, aged 18-75 years without severe comorbidities and contraindications to immunotherapy are enrolled. Eligible patients received A (200 mg/m 2 d1) P (60 mg/m 2 d1- d2) F (600 mg/m 2 CIV120h) induction chemotherapy along with tislelizumab (200 mg d1) every 3 weeks. The curative effect is evaluated (RECIST 1.1) after 3 cycles and a multidisciplinary team discuss whether to perform surgery. For patients undergoing surgery, treatment is completed if there is no residual and extra-capsular lymph node invasion; in case of positive surgical margin, or extracapsular lymph node invasion, or residual lymph nodes, patient will receive concurrent chemoradiotherapy (tumor bed and neck lymph drainage area 66 Gy~70 Gy, P 60 mg/m 2 ). Those not suitable for surgery will receive radical concurrent chemoradiotherapy (GTV 66Gy~70Gy, PTV 50Gy, P 60 mg/m 2 ) within 3 weeks after neoadjuvant treatment. The primary endpoint of efficacy evaluation is the pathological complete response (pCR) rate. Safety evaluation indicators include vital signs, laboratory indicators and adverse events (NCI CTC AE4.0). Results: From Apr 2022 to Jan 2023, 12 patients are screened and enrolled. For the 7 patients who complete 3 cycles of neoadjuvant therapy, 3 patients (42.8%) successfully undergo surgery, with 2 patients (28.5%) achieving pCR and 1 patient (14.3%) achieving major pathological response (MPR). For the other 4 patients, 1 patient (14.3%) achieve pCR by multipoint biopsy of the primary lesion and 2 patients (28.5%) obtain radiologic partial response (PR) by MRI. 1 patient’ lymph nodes tend to increase during radiotherapy and that patient withdraw from clinical trial and undergo salvage surgery. The objective response rate (ORR) of neoadjuvant treatment is 85.7% and pCR rate is 42.9%. Grade 2 or higher AEs during neoadjuvant therapy include grade 2 liver function damage (n = 1, 8.3%), grade 3 myelosuppression (n = 1, 8.3%). 1 (8.3%) patient developed radiation-related oral mucositis (RTOG 2). No other obvious adverse reactions of radiotherapy, chemotherapy or immunotherapy are observed. Conclusions: Combining Tislelizumab with APF followed by surgery or radical concurrent chemoradiotherapy is feasible and effective in patients with locally advanced HNSCC, and further studies are needed to verify its effectiveness and safety.

Efficacy of Brachytherapy Concomitant with Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil in Unresectable Head and Neck Squamous Cell Carcinoma.

Clinical Effect of Iodine 125 Seeds Implantation Synchronized Chemotherapy with Docetaxel, ;Cisplatin,5-Fluorouracil for Unresectable Head and Neck Squamous Cell Carcinoma

Effects Of Radioactive Iodine-125 Seed Implantation On Therapeutic Efficacy, Serum Vegf, Cea Levels, And Prognosis Of Patients With Ocular Malignant Tumors

The efficacy and safety of <SUP>125</SUP>I brachytherapy combined with pre-operative transarterial chemoembolization in patients with locally advanced head and neck cancer

External Beam Radiation Therapy Combined with Individual Template Assisted Iodine125 Radioactive Seed Implant for Head and Neck Squamous Cell Carcinoma

Brachytherapy by Percutaneous Paracentesis Implantation of Iodine-125 Seeds for Lung Cancer

Clinical effectiveness of 125I-seed implantation in combination with nimotuzumab therapy for the advanced oral carcinoma: preliminary results

[Short- to Mid-Term Evaluation of CT-guided 125I Brachytherapy on Recurrent or Metastatic Head and Neck Cancers].

Computed Tomography Fluoroscopy-Guided Percutaneous 125I Seed Implantation for Safe, Effective and Real-Time Monitoring Radiotherapy of Inoperable Stage T1-3N0M0 Non-Small-cell Lung Cancer.

Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.

Clinical Efficacy of CT-guided Iodine-125 Seed Implantation for Recurrent Head and Neck Carcinoma after External Beam Radiotherapy

[Ct-Guidance Interstitial Iodine-125 Seed Brachytherapy As a Salvage Therapy for Recurrent Head and Neck Carcinoma].

Efficacy of radioactive 125I seed implantation in treating inoperable or refused operation head and neck cancers

Efficacy and Safety of CT-Guided 125I Seed Implantation As a Salvage Treatment for Locally Recurrent Head and Neck Soft Tissue Sarcoma after Surgery and External Beam Radiotherapy: A 12-Year Study at a Single Institution

Preliminary Clinical Efficacy of Iodine-125 Seed Implantation for the Treatment of Advanced Malignant Lung Tumors

Long-Term Safety and Efficacy of CT-Guided I125 Radioactive Seed Implantation as a Salvage Therapy for Recurrent Head and Neck Squamous Carcinoma: A Multicenter Retrospective Study

The Efficacy of Volumetric Modulated Arc Therapy Combined with Chemotherapy, Brachytherapy, and Local Hyperthermia on Patients with Locally Advanced Cervical Cancer: A Retrospective Study

The Effectiveness and Prognostic Factors of CT-guided Radioactive Iodine-125 Seed Implantation for the Treatment of Recurrent Head and Neck Cancer after External Beam Radiotherapy.

Combined External Radiotherapy and 125I-Particle Implantation for Treatment of Head and Neck Cancers

Definitive 125I Brachytherapy of Locally Advanced Adenoid Cystic Carcinoma Involving the Skull Base with Satisfying Efficacy and Safety.

An Investigation of 125I Seed Permanent Implantation for Recurrent Carcinoma in the Head and Neck after Surgery and External Beam Radiotherapy